Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Potential Moracin M Prodrugs Strongly Attenuate Airway Inflammation In Vivo

  • Lee, Jongkook (College of Pharmacy, Kangwon National University) ;
  • Mandava, Suresh (College of Pharmacy, Kangwon National University) ;
  • Ahn, Sung-Hoon (College of Pharmacy, Kangwon National University) ;
  • Bae, Myung-Ae (Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology) ;
  • So, Kyung Soo (College of Pharmacy, Kangwon National University) ;
  • Kwon, Ki Sun (College of Pharmacy, Kangwon National University) ;
  • Kim, Hyun Pyo (College of Pharmacy, Kangwon National University)
  • Received : 2019.12.16
  • Accepted : 2020.04.22
  • Published : 2020.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

This study aims to develop new potential therapeutic moracin M prodrugs acting on lung inflammatory disorders. Potential moracin M prodrugs (KW01-KW07) were chemically synthesized to obtain potent orally active derivatives, and their pharmacological activities against lung inflammation were, for the first time, examined in vivo using lipopolysaccharide (LPS)-induced acute lung injury model. In addition, the metabolism of KW02 was also investigated using microsomal stability test and pharmacokinetic study in rats. When orally administered, some of these compounds (30 mg/kg) showed higher inhibitory action against LPS-induced lung inflammation in mice compared to moracin M. Of them, 2-(3,5-bis((dimethylcarbamoyl)oxy)phenyl)benzofuran-6-yl acetate (KW02) showed potent and dose-dependent inhibitory effect on the same animal model of lung inflammation at 1, 3, and 10 mg/kg. This compound at 10 mg/kg also significantly reduced IL-1β concentration in the bronchoalveolar lavage fluid of the inflamed-lungs. KW02 was rapidly metabolized to 5-(6-hydroxybenzofuran-2-yl)-1,3-phenylene bis(dimethylcarbamate) (KW06) and moracin M when it was incubated with rat serum and liver microsome as expected. When KW02 was administered to rats via intravenous or oral route, KW06 was detected in the serum as a metabolite. Thus, it is concluded that KW02 has potent inhibitory action against LPS-induced lung inflammation. It could behave as a potential prodrug of moracin M to effectively treat lung inflammatory disorders.

Keywords

References

  1. Aaron, S. D., Vandemheen, K. L., Maltais, F., Field, S. K., Sin, D. D., Bourbeau, J., Marciniuk, D. D., FitzGerald, J. M., Nair, P. and Mallick, R. (2013) TNF$\alpha$ antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 68, 142-148. https://doi.org/10.1136/thoraxjnl-2012-202432
  2. Arias, L., Vara, Y. and Cossio, F. P. (2012) Regioselective preparation of benzo[b]furans from phenols and $\alpha$-bromoketones. J. Org. Chem. 77, 266-275. https://doi.org/10.1021/jo201841y
  3. Bae, K. H. (2000) The Medicinal Plants of Korea, p. 73. Kyo-Hak Publishing Co., Seoul.
  4. Chapman, R. W., Minnicozzi, M., Celly, C. S., Phillips, J. E., Kung, T. T., Hipkin, R. W., Fan, X., Rindgen, D., Deno, G., Bond, R., Gonsiorek, W., Billah, M. M., Fine, J. S. and Hey, J. A. (2007) A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 322, 486-493. https://doi.org/10.1124/jpet.106.119040
  5. Dentener, M. A., Creutzberg, E. C., Pennings, H. J., Rijkers, G. T., Mercken, E. and Wouters, E. F. (2008) Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 76, 275-282. https://doi.org/10.1159/000117386
  6. Ghosh, A. K. and Brindisi, M. (2015) Organic carbamates in drug design and medicinal chemistry. J. Med. Chem. 58, 2895-2940. https://doi.org/10.1021/jm501371s
  7. Jeffery, P. K. (2001) Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 164, S28-S38. https://doi.org/10.1164/ajrccm.164.supplement_2.2106061
  8. Lee, J. H., Ko, H. J., Woo, E. R., Lee, S. K., Moon, B. S., Lee, C. W., Mandava, S., Samala, M., Lee, J. and Kim, H. P. (2016) Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-$\kappa$B pathways in vitro and in vivo. Eur. J. Pharmacol. 783, 64-72. https://doi.org/10.1016/j.ejphar.2016.04.055
  9. Lee, J. H., Min, D. S., Lee, C. W., Song, K. H., Kim, Y. S. and Kim, H. P. (2018) Ginsenosides from Korean Red Ginseng ameliorate lung inflammatory responses: inhibition of the MAPKs/NF-$\kappa$B/c-Fos pathways. J. Ginseng Res. 42, 476-484. https://doi.org/10.1016/j.jgr.2017.05.005
  10. Lim, H. J., Jin, H. G., Woo, E. R., Lee, S. K. and Kim, H. P. (2013) The root barks of Morus alba and the flavonoid constituents inhibit airway inflammation. J. Ethnopharmacol. 149, 169-175. https://doi.org/10.1016/j.jep.2013.06.017
  11. McAllister, G. D., Hartley, R. C., Dawson, M. J. and Knaggs, A. R. (1998) Total synthesis of moracin C. J. Chem. Soc. Perkin Trans. 1, 3453-3458.
  12. McKittrick, B. A. and Stevenson, R. (1984) Synthesis of the yeast antioxidant benzofuran and analogues. J. Chem. Soc. Perkin Trans. 1, 709-712. https://doi.org/10.1039/p19840000709
  13. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
  14. Tunek, A., Levin, E. and Svensson, L. A. (1988) Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem. Pharmacol. 37, 3867-3876. https://doi.org/10.1016/0006-2952(88)90068-8
  15. Yang, Z. G., Matsuzaki, K., Takamatsu, S. and Kitanaka, S. (2011) Inhibitory effects of constituents from Morus alba var. multicaulis on differentiation of 3T3-L1 cells and nitric oxide production in RAW264.7 cells. Molecules 16, 6010-6022. https://doi.org/10.3390/molecules16076010